<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746315</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20004-Ib</org_study_id>
    <nct_id>NCT02746315</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Single-centre, Placebo-controlled, Dose Escalation, Multiple s.c. DoseStudy to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in China. The aim of this trial is to assess the safety and&#xD;
      tolerability for Multiple s.c injection of HS-20004 in healthy Chinese subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 0 and up to 3 days after last treatment (Day 10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma HS-20004 concentration curve after the last s.c injection</measure>
    <time_frame>Time 0 to 72 hours after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) after the last dose</measure>
    <time_frame>Time 0 to 72 hours after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (tÂ½) for HS-20004 after the last dose</measure>
    <time_frame>Time 0 to 72 hours after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour profiles of plasma glucose and serum insulin from baseline</measure>
    <time_frame>From time 0 to 24 hours after the first and last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-20004</intervention_name>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_label>Experimental 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_label>Experimental 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) between 19 and 28 kg/m^2, inclusive, and a total body weight of&#xD;
             at least 50 kg;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant abnormalities of physical examination, laboratory values, vital&#xD;
             signs or ECG findings at the screening, as judged by the Investigator;&#xD;
&#xD;
          -  Have any other medical abnormality (such as cardiovascular, hepatic, renal,&#xD;
             gastrointestinal, immunologic, hematological, hormonal, metabolic, neoplasmatic or&#xD;
             mental disease), which in the opinion of the investigator, might affect the&#xD;
             absorption, distribution, metabolism, and excretion of the study drug, or prevent the&#xD;
             patient from following and completing the protocol;&#xD;
&#xD;
          -  Family history of diabetes, thyroid cancer, submandibular gland cancer, or history of&#xD;
             pancreatitis, cholelithiasis, drug allergy, serious unconscious hypoglycemia or&#xD;
             positive of anxious chronic viral hepatitis B, HIV antibody;&#xD;
&#xD;
          -  History of drug or alcohol abuse within 6 months before randomization;&#xD;
&#xD;
          -  Use of GLP-1 analogues, DPP-IV enzyme inhibitors, as well as other hypoglycemic drugs&#xD;
             within 3 months before randomization;&#xD;
&#xD;
          -  Use of any prescription drugs and Chinese herbal medicines within 4 weeks before&#xD;
             randomization;&#xD;
&#xD;
          -  Use of non prescription drugs and food supplements (vitamins, etc.) within 2 weeks&#xD;
             before randomization;&#xD;
&#xD;
          -  Participated any drug clinical trials within 3 months, or participated 3 or more than&#xD;
             3 drug clinical trials within 1 year, or had blood donation/loss &gt;400mL within 3&#xD;
             months before randomization;&#xD;
&#xD;
          -  Female subject of childbearing potential who does not use an acceptable method of&#xD;
             birth control, is pregnant or planning a pregnancy, or breastfeeding, or male subject&#xD;
             who does not use an acceptable method of birth control, within six months before&#xD;
             randomization;&#xD;
&#xD;
          -  Subject who cannot refrain from smoking, eating and/or drinking containing&#xD;
             xanthine/caffeine, or strenuous exercise, or others that affect drug absorption,&#xD;
             distribution, metabolism and excretion within 2 days before the study drug&#xD;
             administration; Subject who is unsuitable for inclusion in the study in the opinion of&#xD;
             the investigator;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

